Daiwa Securities Group
DSGN icon

Daiwa Securities Group’s Design Therapeutics DSGN Stock Holding History

Daiwa Securities Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$1K – 1256
2025
Q4 		$1K Hold
100
– – ﹤0.01% 1343
2025
Q3 		$1K Sell
100
-250
-71% -$1.25K ﹤0.01% 1305
2025
Q2 		$1K Hold
350
– – ﹤0.01% 1255
2025
Q1 		$1K Buy
+350
New +$1.67K ﹤0.01% 1221
2023
Q4 		– Sell
-162
Closed – – 1339
2023
Q3 		$0 Hold
162
– – ﹤0.01% 1302
2023
Q2 		$1K Hold
162
– – ﹤0.01% 1268
2023
Q1 		$1K Hold
162
– – ﹤0.01% 1248
2022
Q4 		$2K Hold
162
– – ﹤0.01% 1218
2022
Q3 		$3K Hold
162
– – ﹤0.01% 1190
2022
Q2 		$2K Hold
162
– – ﹤0.01% 1231
2022
Q1 		$3K Hold
162
– – ﹤0.01% 1216
2021
Q4 		$3K Buy
+162
New +$2.78K ﹤0.01% 1239

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Daiwa Securities Group's DSGN Position: Q1 2026 in Review

Daiwa Securities Group sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 100 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in DSGN in Q4 2021 and held it in 12 quarters. The position peaked at $3K in Q3 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Daiwa Securities Group reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 100 Design Therapeutics shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Design Therapeutics in Q4 2021 and held it in 12 quarters.
  • Daiwa Securities Group's Design Therapeutics position peaked at $3K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.